Dr. Marshall E. Kadin is a renowned expert in CD30+ cutaneous T-cell lymphoma (CTCL) at the University of Virginia in Charlottesville, VA. He was the first to describe lymphomatoid papulosis as a cutaneous proliferation of activated T cells.
Dr. Kadin also played a key role in establishing methotrexate as an effective therapy for CD30-positive lymphoproliferative disorders. He developed five lymphoma cell lines, which have been widely distributed for research and have contributed to significant discoveries in T-cell lymphoma biology.
🏥 University Affiliation, City, Country: University of Virginia, Charlottesville, VA, USA
🧪 Area of Focus in Clinical Practice and Research: CD30+ CTCL
🔎 Looking forward to in the field of cutaneous lymphomas and at the 6th WCCL: Advancing our understanding of lymphoma pathogenesis
💭 What are you passionate about in medicine or recreationally?
Understanding the pathogenesis of lymphomas
🏆 A short story or academic achievement you are proud of:
Describing lymphomatoid papulosis and contributing to the development of key lymphoma cell lines for research
🌟 Secret to Career Success: Perseverance